<code id='B1850CDA62'></code><style id='B1850CDA62'></style>
      • <acronym id='B1850CDA62'></acronym>
      <center id='B1850CDA62'><center id='B1850CDA62'><tfoot id='B1850CDA62'></tfoot></center><abbr id='B1850CDA62'><dir id='B1850CDA62'><tfoot id='B1850CDA62'></tfoot><noframes id='B1850CDA62'>
      • <optgroup id='B1850CDA62'><strike id='B1850CDA62'><sup id='B1850CDA62'></sup></strike><code id='B1850CDA62'></code></optgroup>
        5. <b id='B1850CDA62'><label id='B1850CDA62'><select id='B1850CDA62'><dt id='B1850CDA62'><span id='B1850CDA62'></span></dt></select></label></b><u id='B1850CDA62'></u>
          <i id='B1850CDA62'><strike id='B1850CDA62'><tt id='B1850CDA62'><pre id='B1850CDA62'></pre></tt></strike></i>
          
    
          
      
          
       
      
          
        
      
          
      
          
        
          
          
          
            
          
            
          
              
          
                
          focus 
          
                
          
                
          
              
          
            
          
            
            
          
          
          
       
        
          
      
          
      
          
        
          
        
          
          
            
          
                           
          focus  
          
                                   
                 
                                      author：comprehensive   
                                        
                                      
                                      Page View：36134
                                  
                                    
          
                                    
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand.																									Adobe 
          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.
          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.
          advertisement
          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation
                                
                            
          Next article：  
                                      
                                          Alkermes shareholders re
                                                                    
          
            
          
           
            
          
          
          
       
          
        
          
        
      
          
      
          
                                                
        
          comprehensive
          
                  
          

                    
          
            
          
              
                The cancer drug shortage isn’t new — and neither are the solutions
                
          
                        
              
          
                The cancer drug shortage isn’t new — and neither are the solutions
                
          
                  
          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
                   
          
            
          
              
                Dispute over threat of extinction posed by artificial intelligence looms over surging industry
                
          
                        
              
          
                Dispute over threat of extinction posed by artificial intelligence looms over surging industry
                
          
                  
          5:08Advancedhumanoidrobot'Sophia'ispicturedatAIforGoodGlobalSummit,inGeneva,Switzerland,July6,2023.P
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
                   
          
            
          
              
                In age of alternative facts, a scholarly course on calling out crap
                
          
                        
              
          
                In age of alternative facts, a scholarly course on calling out crap
                
          
                  
          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
         
        
          
          
        
          

          
          
            
          
          
          
            
          The FDA weighs the risks of candy
          
            
          AdobeWASHINGTON—M&Ms,Reese’s,gummybears,andevencottoncandymadeanappearanceattheFoodandDrugAdmini
          
          
          
          
          
            read more